The money is pledged. The public test is delivery.

At a New York meeting on the Ebola response, governments and partners announced cash and in-kind commitments that Africa CDC describes as approximately US$2.9 billion. The agency says financing must reach nationally led treatment, surveillance and cross-border work quickly. Reuters separately reported an additional US pledge of US$267 million announced on 23 September.

A commitment is neither a disbursement nor a contained outbreak. For the Democratic Republic of Congo and its neighbours, the useful public measure is how much arrives, where it goes and whether it closes identifiable gaps in contact tracing, protective equipment and care. Africa CDC itself calls for those flows to be traceable.

NOAA forecasts at least three consecutive days of abnormal heat in north-western Kenya and northern Uganda, alongside several other African areas. It also identifies deteriorated vegetation following prolonged rainfall deficits in northern Uganda and parts of Ethiopia. Heavy rain and elevated flood potential are forecast in parts of West Africa and along the Nigeria–Cameroon border.

These are short-range forecasts, not recorded deaths or damage. A heat alert for north-western Kenya calls for different operations from a flood warning in Senegal or Nigeria, while the vegetation findings point to conditions already observed.

Uganda’s finance ministry’s annual debt bulletin, published on 15 September, put public debt at US$37.1 billion at the end of June 2026, against US$32.3 billion in June 2025. Reuters reported the figures on 24 September. The bulletin puts nominal debt at 54.3% of GDP, up from 51.3%, with the domestic share rising. The September news report drew renewed attention to an earlier ministry release; the debt figures themselves were not published on 24 September.

The ministry’s risk table shows interest payments rising from 4.4% to 4.9% of GDP. Average time to maturity lengthened from 8.5 to 8.8 years, while the share of total debt maturing within one year rose from 11.2% to 13.0%. A longer average maturity therefore does not settle the near-term refinancing question. Nor does the stock alone show whether the borrowing financed valuable public investments.

A Blue Cross Blue Shield Association analysis of US inpatient claims attributes US$942 million in additional costs across 2024–25, relative to 2023, to more intensive billing. Reuters reports the insurers’ concern that AI-assisted record review and clinical-note tools may identify more billable secondary conditions. In examples it examined, the association says more complex coding did not consistently coincide with more treatment.

This is an insurer’s interpretation of its claims. It does not prove that AI caused every additional charge or that the patients did not need care. The US amount must not be presented as a Kenyan estimate.

A new WHO guideline examines three methods not previously included in its contraceptive guidance: ormeloxifene, quinestrol-containing pills and mifepristone for emergency contraception. It also examines continuous or extended use of combined oral pills and extended use of the etonogestrel implant. WHO says the recommendations draw on reviews of effectiveness, safety and acceptability.

The guideline does not mean that every method is licensed, stocked or appropriate for every patient in every country. Its policy value lies in giving ministries and professional bodies evidence to examine, including where existing national practice differs.